Eli Lilly

Drug Companies Back Again to Protect Patents for Biologics and Insulin

SB 147, as heard by the Senate Health Committee, would lift an expiration date on a law that restricts pharmacists’ ability to prescribe biosimilars, or generic alternatives to complex biological drugs. The bill also expands that law to include insulin. California Gov. Jerry Brown vetoed a very similar law, citing increased costs to state-purchased health plans.

Like a clump of Scotch broom sprouting each year on Oregon hillsides no matter how many times it gets pulled, the pharmaceutical companies are repeating their efforts from past sessions to restrict the ability of pharmacists to dispense generic or “biosimilar” alternatives to so-called biological

Eli Lilly Amendment Exits Oregon Legislature as it Entered: Quietly

House Bill 4110 passes the House, requiring insurance companies to maintain coverage for people in police custody awaiting trial, putting taxpayers off the hook for those medical expenses.

The amendment that would restrict pharmacists from dispensing generic insulin slipped out of the Capitol in the same way it appeared -- quietly, in an irregular committee at an odd hour.

The Joint Capital Construction budget subcommittee voted to delete the amendment from House Bill 4110 at its 7:45 p.m. meeting on Wednesday. The full Ways & Means Committee approved HB 4110 without the amendment at its 8 p.m. meeting on Thursday.

Hoyle Pushes Amendment for Eli Lilly, Limiting Generic Insulin for Diabetics

The amendment to House Bill 4110 would require pharmacists to get special permission from doctors to prescribe generic insulin, which could hit the market as early as next year. The Eli Lilly amendment threatens the underlying bill, which requires insurance companies to pay for medical costs when an insured person is in police custody but not convicted of a crime.

House Majority Leader Val Hoyle, D-Eugene, has slipped an amendment for pharmaceutical giant Eli Lilly into an unrelated healthcare bill that will protect its patented insulin drug against generic competition while Eli L

Subscribe to Eli Lilly